![Tom Powles: Belzutifan significantly outperformed Everolimus in heavily pretreated clear cell renal cancer](https://oncodaily.com/pub/uploads/2024/07/47952377700-e1720890006102.png)
Photo of Thomas Powles from bartscancer.london
Aug 26, 2024, 20:08
Tom Powles: Belzutifan significantly outperformed Everolimus in heavily pretreated clear cell renal cancer
Tom Powles, Professor of urology cancer at the University of London and the Director of Barts Cancer Centre, shared a post on X:
“Belzutifan significantly outperformed everolimus in heavily pretreated clear cell renal cancer.
Respiratory Rate, Progression-free survival , Quality of life but no Oculus Sinister. Data suggests belzutifan is better in less heavily treated disease and in combination. 1st line and adjuvant trials awaited.”
Source: Tom Powles/X
Aug 26, 2024, 20:02